comparemela.com

Latest Breaking News On - Capitello 291 - Page 1 : comparemela.com

Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-resistant Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Results from the Phase III CAPItello-291 Trial

Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022.

Aromatase inhibitor resistant hormoneHuman epidermal growth factor receptorAdvanced breast cancerBreast cancerHr breast cancerHer2 breast cancerCapitello trialCapitello 291Jcdk4 6 inhibitorPik3ca alterationAkt1 alterationPten alterationCapivasertib adverse eventsAdverse eventsFulvestrant capivasertibFulvestrant adverse events

HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.

Aditya bardiaGregory vidalKomal jhaveriHr her2 breast cancerCdk4 6 inhibitorsSecond line therapiesEndocrine therapyEndocrine resistanceAkt inhibitorsCapitello 291Maintain trialEmber 3Oral serdsViktoria 1

vimarsana © 2020. All Rights Reserved.